Tiragolumab (Anti-TIGIT antibody) in combination with ICIs (atezolizumab) demonstrated a clinical benefit in PD-L1 > 1% NSCLC with an ORR of 31.3% (95% CI 19.5–43.2) compared to 16.2% (95% CI 6.7–25.7, p = 0.031) in the single-agent atezolizumab group and a slight benefit in progression-free survival of 5.4 (95% CI 4.2-not estimable) vs. 3.6 months (2.7–4.4 months) in the single-agent atezolizumab group [47] (Table 2). This evidence concerns the gene CD274 and non-small cell lung carcinoma.